Not Another Opana: US FDA Panel Rejects PTI’s Remoxy On Intravenous Abuse Concerns
Executive Summary
Studies showing oxycodone could be extracted for intravenous use troubled advisory committee members, who worried it would result in the same types of adverse public health effects that led to market withdrawal of Endo’s Opana ER; panelists also were concerned about the ability to partially defeat Remoxy’s extended-release properties by chewing the product.
You may also be interested in...
Pain Therapeutics Appeals Remoxy CRL In Likely Last Ditch Effort To Save Abuse-Deterrent Opioid
Meeting with US FDA in January will aim to reverse fourth rejection in 10 years; firm still criticizing agency even as it works to reconcile their positions.
PMRS Continues Campaign Against Other Abuse Deterrent Opioid Products
Latest citizen petition seeks to halt US FDA approval of Mallinckrodt's immediate release oxycodone abuse deterrent formulation; user fee action date is Nov. 16.
Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel
FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.